Entrada Therapeutics has shared an update with the Duchenne community on the continued progress of its ELEVATE-44-201 and ELEVATE-45-201 clinical studies. This includes revised timelines for study data readouts, now expected later in 2026 and into early 2027, as well as the acceptance of its long-term extension study, ENTR-DMD-202 by authorities in the UK and Europe. Entrada thanks all clinical study participants whose commitment is helping advance potential therapies for those living with Duchenne.
The company also highlighted recent community events they attended, including Jett Foundation’s Silver Soiree in Quincy, MA, and shared upcoming events they plan to participate in, like Camp Promise – Southeast, Camp Promise – East, the World Duchenne Awareness Day Luncheon on September 13th, and Jett Foundation’s New York Family Workshops in October.
For more information, please visit their latest issue of their quarterly community newsletter.